Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N‑phenyl‑1H‑pyrrolo[2,3-b]pyridin‑3‑amine is a synthetic small molecule belonging to the pyrrolopyridine class of organic compounds. It features a fused bicyclic structure with both pyrrole and pyridine rings and an aniline (N–phenyl) substitution at the 3-position. The compound has been studied as a kinase inhibitor—specifically targeting serine/threonine-protein kinase pim‐1—and is of interest in medicinal chemistry for its potential anti-cancer properties due to its ability to inhibit cell proliferation pathways. Its molecular formula is C13H11N3 and it has a molecular weight of approximately 209.25 g/mol. The compound appears as a solid under standard conditions and demonstrates moderate lipophilicity (logP ~ 2.7–3.4)[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine.